Quick Answer
ACTUATE THERAPEUTICS, INC. reported Research And Development Expense of $10.29 million for the year ending 2025.
- ACTUATE THERAPEUTICS, INC. showed a decrease of -44.9% in Research And Development Expense from 2024 to 2025.
- This data is from ACTUATE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2023: $4.78 million | Q3 2023: $5.76 million | Q1 2024: $6.86 million | Q2 2024: $4.37 million | Q3 2024: $3.76 million | Q1 2025: $3.22 million | Q2 2025: $2.76 million | Q3 2025: $2.18 million.
- Over the full 3 years of available data (2023 to 2025), ACTUATE THERAPEUTICS, INC.'s Research And Development Expense has declined by 52.6%.
- Historical annual values: Fiscal year 2025: $10.29 million | Fiscal year 2024: $18.68 million | Fiscal year 2023: $21.71 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: